Potential for targeted therapy of eIF2, a PKR-related molecule involved in carcinogenesis and progression of hepatocellular carcinoma.

• Project/Area Number: 21K08008
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Ehime University
• Principal Investigator: Hiasa Yoichi 愛媛大学, 医学系研究科, 教授 (70314961)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Project Status: Completed (Fiscal Year 2023)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: Protein kinase R / eIF2 / eIF2-alpha / eIF2-beta / eIF2-gamma / Hepatocellular carcinoma / Tumor proliferation / Apoptosis / PKR / PERK / 肝細胞癌 / eIF2B / protein kinase R / hepatocellular carcinoma

Outline of Research at the Start

肝細胞がんは死亡数が多く、治療が難しいがんとして知られている。肝細胞がんではウイルス感染を防ぐ役割をもつPKR蛋白が高発現している。しかし、PKRによりリン酸化されることで働きが抑制されるとされるeIF2の役割はよくわかっていない。eIF2は蛋白合成に関わることから、肝細胞がんでのこの分子の役割を明らかにするとともに、肝細胞がんの増殖の抑制、がん抑制治療の標的分子としての可能性について研究する。

Outline of Final Research Achievements

Protein kinase R (PKR) is known to be overexpressed and contribute to proliferation of hepatocellular carcinoma (HCC). In this study, I focused on eIF2, a translation initiation factor as a PKR-related molecule. In HCC patients with high expression of eIF2, had a poorer prognosis than those with low expression. In addition, the knockdown of eIF2 reduced the proliferative potential of HCC. The eIF2 is consisted by three subunits, and we revealed that the effect of each subunit on HCC was different. The eIF2α is well known to be associated with repression of RNA translation and apoptosis. However, the changes of eIF2β and eIF2γ, whose functions have not yet been clarified, had a greater impact on the progression of HCC compared to eIF2α. This study suggests that regulation of eIF2β and eIF2γ in the PKR-eIF2 pathway, would have some potentials as target therapies against HCC.

Academic Significance and Societal Importance of the Research Achievements

本研究ではPKR関連分子であるeIF2が肝細胞がんの予後に影響していることを明らかにした。
PKRをはじめとする上流シグナルによってeIF2αがリン酸化されることは知られているが、肝細胞がんにおいてPKR-eIF2α経路が発がんまたはがんの進展に及ぼす影響は明らかでない。本研究では、未だ作用について不明な点の多いeIF2βとeIF2γの発現抑制が腫瘍増殖能を抑制することを見出した。
翻訳開始因子であるeIF2の制御機序の解明は、肝細胞がんのみならず、様々な悪性腫瘍の分子標的治療に結び付く可能性がある。

Research Products

• [Journal Article] C16, a PKR inhibitor, suppresses cell proliferation by regulating the cell cycle via p21 in colorectal cancer (2024)
  • Author(s): Hashimoto Yu、Tokumoto Yoshio、Hiasa Yoichi、et al.
  • Journal Title: Scientific Reports Volume: 14 Issue: 1 Pages: 9029-9029
  • DOI: 10.1038/s41598-024-59671-7
  • Peer Reviewed / Open Access
• [Journal Article] Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation (2023)
  • Author(s): Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
  • Journal Title: Oncology Volume: 102 Issue: 4 Pages: 291-298
  • DOI: 10.1159/000533672
  • Peer Reviewed
• [Journal Article] Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era (2023)
  • Author(s): Nakamura Yoshiko、Hirooka Masashi、Hiraoka Atsushi、Koizumi Yohei、Yano Ryo、Morita Makoto、Okazaki Yuki、Imai Yusuke、Ohama Hideko、Hirooka Kana、Watanabe Takao、Tada Fujimasa、Yoshida Osamu、Tokumoto Yoshio、Abe Masanori、Hiasa Yoichi
  • Journal Title: Cancers Volume: 15 Issue: 21 Pages: 5298-5298
  • DOI: 10.3390/cancers15215298
  • Peer Reviewed / Open Access
• [Journal Article] Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria (2023)
  • Author(s): Ohama Hideko、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Oncology Volume: 101 Issue: 9 Pages: 575-583
  • DOI: 10.1159/000530987
  • Peer Reviewed
• [Journal Article] Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function (2023)
  • Author(s): Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al.
  • Journal Title: Oncology Volume: 101 Issue: 10 Pages: 624-633
  • DOI: 10.1159/000531316
  • Peer Reviewed
• [Journal Article] Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab (2023)
  • Author(s): Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al.
  • Journal Title: Hepatology Research Volume: 53 Issue: 10 Pages: 1031-1042
  • DOI: 10.1111/hepr.13934
  • Peer Reviewed
• [Journal Article] Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals (2023)
  • Author(s): Watanabe Takao、Tokumoto Yoshio、Hiasa Yoichi、et al.
  • Journal Title: Scientific Reports Volume: 13 Issue: 1 Pages: 8992-8992
  • DOI: 10.1038/s41598-023-36052-0
  • Peer Reviewed / Open Access
• [Journal Article] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients (2023)
  • Author(s): Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, et al.
  • Journal Title: Journal of Cancer Research and Clinical Oncology Volume: ー Issue: 10 Pages: 7565-7577
  • DOI: 10.1007/s00432-023-04678-2
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Cancer Medicine Volume: 11 Issue: 20 Pages: 3796-3808
  • DOI: 10.1002/cam4.4763
  • Peer Reviewed / Open Access
• [Journal Article] Does first‐line treatment have prognostic impact for unresectable HCC? -Atezolizumab plus bevacizumab versus lenvatinib (2022)
  • Author(s): Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al.
  • Journal Title: Cancer Medicine Volume: 12 Issue: 1 Pages: 325-334
  • DOI: 10.1002/cam4.4854
  • Peer Reviewed / Open Access
• [Journal Article] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. (2022)
  • Author(s): Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Nishida N, et al.
  • Journal Title: European journal of cancer Volume: 180 Pages: 9-20
  • DOI: 10.1016/j.ejca.2022.11.017
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice (2022)
  • Author(s): Tanaka Takaaki、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al.
  • Journal Title: Hepatology Research Volume: 52 Issue: 9 Pages: 773-783
  • DOI: 10.1111/hepr.13797
  • Peer Reviewed
• [Journal Article] C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Scientific Reports Volume: 12 Issue: 1 Pages: 8421-8421
  • DOI: 10.1038/s41598-022-12058-y
  • Peer Reviewed / Open Access
• [Journal Article] Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma (2022)
  • Author(s): Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
  • Journal Title: Cancers Volume: 15 Issue: 1 Pages: 236-236
  • DOI: 10.3390/cancers15010236
  • Peer Reviewed / Open Access
• [Journal Article] Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: European Journal of Gastroenterology and Hepatology Volume: 34 Issue: 8 Pages: 857-864
  • DOI: 10.1097/meg.0000000000002398
  • Peer Reviewed
• [Journal Article] Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma (2022)
  • Author(s): Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al.
  • Journal Title: Oncology Volume: 100 Issue: 12 Pages: 645-654
  • DOI: 10.1159/000526521
  • Peer Reviewed
• [Journal Article] Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis (2022)
  • Author(s): Hatanaka Takeshi、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al.
  • Journal Title: Hepatology Research Volume: 52 Issue: 5 Pages: 462-470
  • DOI: 10.1111/hepr.13748
  • Peer Reviewed
• [Journal Article] Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: European Journal of Gastroenterology and Hepatology Volume: 34 Issue: 6 Pages: 698-706
  • DOI: 10.1097/meg.0000000000002356
  • Peer Reviewed
• [Journal Article] A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study (2022)
  • Author(s): Liu Chuan、Cao Zhujun、Yan Huadong、Hiasa Yoichi、et al.
  • Journal Title: American Journal of Gastroenterology Volume: 117 Issue: 10 Pages: 1605-1613
  • DOI: 10.14309/ajg.0000000000001873
  • Peer Reviewed
• [Journal Article] Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment (2022)
  • Author(s): Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
  • Journal Title: Cancers Volume: 14 Issue: 22 Pages: 5524-5524
  • DOI: 10.3390/cancers14225524
  • Peer Reviewed / Open Access
• [Journal Article] Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study (2022)
  • Author(s): Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Hepatology International Volume: 16 Issue: 5 Pages: 1150-1160
  • DOI: 10.1007/s12072-022-10358-z
  • Peer Reviewed
• [Journal Article] Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Oncology Volume: 101 Issue: 4 Pages: 270-282
  • DOI: 10.1159/000527676
  • Peer Reviewed
• [Journal Article] New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study (2022)
  • Author(s): Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Cancer Medicine Volume: 12 Issue: 6 Pages: 6980-6993
  • DOI: 10.1002/cam4.5495
  • Peer Reviewed / Open Access
• [Journal Article] Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study (2022)
  • Author(s): Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Cancer Medicine Volume: 12 Issue: 5 Pages: 5293-5303
  • DOI: 10.1002/cam4.5337
  • Peer Reviewed / Open Access
• [Journal Article] Development and validation of a modified albumin?bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (2022)
  • Author(s): Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Hepatology International Volume: 17 Issue: 1 Pages: 86-96
  • DOI: 10.1007/s12072-022-10406-8
  • Peer Reviewed
• [Journal Article] The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis (2022)
  • Author(s): Hatanaka Takeshi、Naganuma Atsushi、Hiraoka Atsushi、Hiasa Yoichi、et al.
  • Journal Title: Cancer Medicine Volume: 12 Issue: 4 Pages: 4259-4269
  • DOI: 10.1002/cam4.5294
  • Peer Reviewed / Open Access
• [Journal Article] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience (2022)
  • Author(s): Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Ohama H、Nouso K、Morishita A、Tsutsui A、Nagano T、Itokawa N、Hiasa Y、Kudo M、et al.
  • Journal Title: Cancer Reports Volume: 5 Issue: 2
  • DOI: 10.1002/cnr2.1464
  • Peer Reviewed / Open Access
• [Journal Article] Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria ? Multicenter analysis (2022)
  • Author(s): Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Kakizaki S、Shimada N、Kawata K、Naganuma A、Tanaka T、Ohama H、Nouso K、Morishita A、Hiasa Y、Kudo M、et al.
  • Journal Title: Hepatology Research Volume: 52 Issue: 3 Pages: 308-316
  • DOI: 10.1111/hepr.13734
  • Peer Reviewed
• [Journal Article] Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in non-viral hepatocellular carcinoma (2022)
  • Author(s): Matsui T, Hamada TS, Naito Y, Nojima M, Iio E, Tamori A, Kubo S, Ide T, Kondo Y, Eguchi Y, Komori A, Morine Y, Shimada M, Utsunomiya T, Kimura K, Hiasa Y, Ochiya T, Naiki A, Takahashi S, Tanaka Y
  • Journal Title: Hepatol Res. Volume: 52(1) Issue: 1 Pages: 93-104
  • DOI: 10.1111/hepr.13674
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Impact of modified albumin?bilirubin grade on survival in patients with HCC who received lenvatinib (2021)
  • Author(s): Tada T、Kumada T、Hiraoka A、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Tani J、Nakamura S、Nouso K、Tsutsui A、Nagano T、Takaaki T、Hiasa Y、et al.
  • Journal Title: Scientific Reports Volume: 11 Issue: 1 Pages: 14474-14474
  • DOI: 10.1038/s41598-021-93794-5
  • Peer Reviewed / Open Access
• [Journal Article] Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study (2021)
  • Author(s): Rimini M、Shimose S、Lonardi S、Tada T、Masi G、Iwamoto H、Lai E、Burgio V、Hiraoka A、Ishikawa T、Solda C、Shirono T、Vivaldi C、Takaguchi K、Shimada N、Astara G、Koga H、Nouso K、Joko K、Torimura T、Hiasa Y、Salani F、Scartozzi M、Cascinu S、Casadei GA.
  • Journal Title: Hepatology Research Volume: 51 Issue: 12 Pages: 1229-1241
  • DOI: 10.1111/hepr.13718
  • Peer Reviewed
• [Journal Article] Radiofrequency Ablation Covering the Entire Tumor Blood Drainage Area Improves Survival in Hepatocellular Carcinoma (2021)
  • Author(s): Hirooka M、Koizumi Y、Tanaka T、Sunago K、Nakamura Y、Watanabe T、Yoshida O、Tokumoto Y、Abe M、Hiasa Y.
  • Journal Title: Hepatology Communications Volume: 5 Issue: 7 Pages: 1300-1309
  • DOI: 10.1002/hep4.1703
  • Peer Reviewed / Open Access
• [Journal Article] Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression (2021)
  • Author(s): Hiraoka A、Kumada T、Hatanaka T、Tada T、Kariyama K、Tani J、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Ogawa C、Tamai T、Kakizaki S、Tojima H、Hiasa Y、Kudo M、et al.
  • Journal Title: Hepatology Research Volume: 51 Issue: 8 Pages: 880-889
  • DOI: 10.1111/hepr.13644
  • Peer Reviewed
• [Journal Article] AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy. (2021)
  • Author(s): Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y
  • Journal Title: BMC Cancer Volume: 14;21(1) Issue: 1 Pages: 699-699
  • DOI: 10.1186/s12885-021-08401-7
  • Peer Reviewed / Open Access
• [Journal Article] The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells (2021)
  • Author(s): Yukimoto Atsushi、Watanabe Takao、Sunago Kotaro、Nakamura Yoshiko、Tanaka Takaaki、Koizumi Yohei、Yoshida Osamu、Tokumoto Yoshio、Hirooka Masashi、Abe Masanori、Hiasa Yoichi
  • Journal Title: Scientific Reports Volume: 11 Issue: 1 Pages: 7926-7926
  • DOI: 10.1038/s41598-021-86592-6
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study (2021)
  • Author(s): Hiraoka A、Kumada T、Tada T、Tani J、Kariyama K、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Aoki T、Tanaka T、Ohama H、Hiasa Y、Kudo M、et al.
  • Journal Title: Scientific Reports Volume: 11 Issue: 1 Pages: 16663-16663
  • DOI: 10.1038/s41598-021-96089-x
  • Peer Reviewed / Open Access
• [Journal Article] Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib (2021)
  • Author(s): Rapposelli IG、Tada T、Shimose S、Burgio V、Kumada T、Iwamoto H、Hiraoka A、Niizeki T、Atsukawa M、Koga H、Hirooka M、Torimura T、Iavarone M、Tortora R、Campani C、Lonardi S、Tamburini E、Piscaglia F、Masi G、Cabibbo G、Giuseppe FF、Silletta M、Tsuji K、Ishikawa T、Hiasa Y、Casadei GA、et al.
  • Journal Title: Liver International Volume: 41 Issue: 12 Pages: 2997-3008
  • DOI: 10.1111/liv.15014
  • Peer Reviewed
• [Journal Article] Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis (2021)
  • Author(s): Tada T、Kumada T、Hiraoka A、Michitaka K、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Nakamura S、Nouso K、Tsutsui A、Nagano T、Hiasa Y、et al.
  • Journal Title: Oncology Volume: 99 Issue: 8 Pages: 518-527
  • DOI: 10.1159/000515896
  • Peer Reviewed
• [Presentation] C型肝硬変におけるSVR後の肝予備能と肝発癌の予測 (2023)
  • Author(s): 渡辺崇夫、徳本良雄一、日浅陽一
  • Organizer: 第59回日本肝臓学会総会
• [Presentation] 門脈圧亢進症を伴った切除不能肝細胞癌患者におけるAtezolizumab+Bevacizumabの治療成績 (2023)
  • Author(s): 多田藤政、多田俊史、日浅陽一 他
  • Organizer: 第28回日本肝がん分子標的治療研究会
• [Presentation] 初回治療として根治術を施行した肝細胞癌患者におけるSVR時期と予後の検討 (2023)
  • Author(s): 多田藤政、中谷康輔、日浅陽一 他
  • Organizer: 第45回日本肝臓学会西部会
• [Presentation] Clinical usefulness of lenvatinib as second-line treatment for hepatocellular carcinoma following atezolizumab plus bevacizumab failure. (2023)
  • Author(s): Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al.
  • Organizer: American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2023
  • Int'l Joint Research
• [Presentation] Atezolizumab plus bevacizumab therapy for hepatocellular carcinoma: The Geriatric Nutritional Risk Index as a convenient prognostic evaluation tool. (2023)
  • Author(s): Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al.
  • Organizer: American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2023
  • Int'l Joint Research
• [Book] 今日の治療指針 202年版: 私はこう治療している (2024)
  • Author(s): 日浅陽一 (編)福井次矢、高木 誠、小室一成
  • Total Pages: 2224
  • Publisher: 医学書院
  • ISBN: 9784260053426
• [Book] 消化器内科診療Controversy (2023)
  • Author(s): 廣岡昌史、日浅陽一 (編)竹原徹郎
  • Total Pages: 406
  • Publisher: 中外医学社
  • ISBN: 9784498140523
• [Book] 解剖生理からみちびく消化器ケア Q＆A108: イラスト×写真で機能・検査・疾患・治療・ケアのギモンが解決！ (2023)
  • Author(s): 廣岡昌史、日浅陽一 (編)李 相雄
  • Total Pages: 256
  • Publisher: メディカ出版
  • ISBN: 9784840480260